JJ Hagan, DN Middlemiss, PC Sharpe… - Trends in …, 1997 - cell.com
l-Dopa has long been the mainstay of therapy for Parkinson'sdisease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and …
AR Carta - Current drug targets, 2013 - ingentaconnect.com
… for the pathobiology of Parkinson'sdisease. Antioxid Redox … of Parkinson'sdisease. Prog Neurobiol 2009; 89: 277-87. … Alzheimer's and de novo Parkinson'sdisease patients. Neurosci …
Parkinson’s disease (PD) is a neurodegenerative disorder pathologically distinguished by degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle rigidity, …
PD is an attractive target for central nervous system (CNS) gene therapy for several reasons. First, the pathology in early PD is, to a first approximation, limited to dopaminergic neurons …
E Fernandez-Espejo - Molecular neurobiology, 2004 - Springer
Parkinson’s disease (PD) is caused by the degeneration of dopaminergic neurons of substantia nigra projecting to striatum. The cause of idiopathic PD is obscure, and most cases are …
SB Dunnett, A Björklund - Nature, 1999 - nature.com
… disease now offers novel prospects for therapy based on targeted neuroprotection of vulnerable neurons and effective strategies for their replacement. Parkinson'sdisease … Parkinson in …
A Björklund - … Cells: Nuclear Reprogramming and Therapeutic …, 2005 - Wiley Online Library
Cell replacement therapy in Parkinson'sdisease (PD) has so far been based on the use of primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses. …
A Paul, KS Yadav - Journal of Drug Delivery Science and Technology, 2020 - Elsevier
… in medical history for James Parkinson's by addition of more symptoms to … Parkinson's disease (PD) for those symptoms [4]. Being the second most familiar ND after Alzheimer's disease …
JA Pawitan - Anatomy & cell biology, 2011 - synapse.koreamed.org
… be promising for treating Parkinson’s disease in the future. Therefore, this review addresses those cells in terms of their prospects in cell therapy for Parkinson’s disease. In addition, the …